Yinfeng Zhang1, Jessica M Fogel1, Xu Guo2, William Clarke1, Autumn Breaud1, Vanessa Cummings1, Erica L Hamilton3, Arthur Ogendo4, Noel Kayange5, Ravindre Panchia6, Karen Dominguez7, Ying Q Chen2, Theodorus Sandfort8, Susan H Eshleman1. 1. Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 3. Science Facilitation Department, FHI 360, Durham, North Carolina, USA. 4. Kenya Medical Research Institute (KEMRI) CDC, Kisumu, Kenya. 5. College of Medicine - Johns Hopkins Project, Blantyre, Malawi. 6. Perinatal HIV Research Unit, University of the Witwatersrand, Soweto HPTN CRS, Soweto. 7. Desmond Tutu HIV Centre, UCT Medical School, Cape Town, South Africa. 8. HIV Center for Clinical and Behavioral Studies, Columbia University, New York, New York, USA.
Abstract
OBJECTIVE: To analyze antiretroviral drug use and HIV drug resistance among HIV-infected MSM and transgender women who were screened for participation in the HIV Prevention Trials Network 075 study. METHODS: A qualitative assay was used to detect 20 antiretroviral drugs in five drug classes; this assay is based on liquid chromatography coupled with high-resolution accurate-mass mass spectrometry. HIV viral load testing was performed using the RealTime HIV-1 Viral Load Assay. HIV drug resistance testing was performed using the ViroSeq HIV-1 Genotyping System. Logistic regression was used to evaluate factors associated with study outcomes. RESULTS: Antiretroviral drugs were detected in 63 (34.4%) of 183 participants who had confirmed HIV infection at screening; 11 (17.5%) of the 63 participants were not virally suppressed. Six (54.5%) of the 11 participants had drug-resistant HIV, including four who had multiclass resistance. Seven (63.6%) of the 11 were at risk of acquiring resistance to additional antiretroviral drugs. In multivariate model, antiretroviral drugs were more frequently detected in older participants, those recruited from Kisumu, Kenya, and those who reported ever having been in HIV care or on antiretroviral therapy (ART). CONCLUSION: Most of HIV-infected persons screened for participation in HIV Prevention Trials Network 075 were not on ART, and many of those who were on ART were not virally suppressed. Many of those participants had drug-resistant HIV. These findings highlight the need for improved HIV care for African MSM and transgender women.
OBJECTIVE: To analyze antiretroviral drug use and HIV drug resistance among HIV-infected MSM and transgender women who were screened for participation in the HIV Prevention Trials Network 075 study. METHODS: A qualitative assay was used to detect 20 antiretroviral drugs in five drug classes; this assay is based on liquid chromatography coupled with high-resolution accurate-mass mass spectrometry. HIV viral load testing was performed using the RealTime HIV-1 Viral Load Assay. HIV drug resistance testing was performed using the ViroSeq HIV-1 Genotyping System. Logistic regression was used to evaluate factors associated with study outcomes. RESULTS: Antiretroviral drugs were detected in 63 (34.4%) of 183 participants who had confirmed HIV infection at screening; 11 (17.5%) of the 63 participants were not virally suppressed. Six (54.5%) of the 11 participants had drug-resistant HIV, including four who had multiclass resistance. Seven (63.6%) of the 11 were at risk of acquiring resistance to additional antiretroviral drugs. In multivariate model, antiretroviral drugs were more frequently detected in older participants, those recruited from Kisumu, Kenya, and those who reported ever having been in HIV care or on antiretroviral therapy (ART). CONCLUSION: Most of HIV-infectedpersons screened for participation in HIV Prevention Trials Network 075 were not on ART, and many of those who were on ART were not virally suppressed. Many of those participants had drug-resistant HIV. These findings highlight the need for improved HIV care for African MSM and transgender women.
Authors: Chris Beyrer; Stefan D Baral; Frits van Griensven; Steven M Goodreau; Suwat Chariyalertsak; Andrea L Wirtz; Ron Brookmeyer Journal: Lancet Date: 2012-07-20 Impact factor: 79.321
Authors: Mohammed Dahoma; Lisa G Johnston; Abigail Holman; Leigh Ann Miller; Mahmoud Mussa; Asha Othman; Ahmed Khatib; Ramadhan Issa; Carl Kendall; Andrea A Kim Journal: AIDS Behav Date: 2011-01
Authors: Heather Fay; Stefan D Baral; Gift Trapence; Felistus Motimedi; Eric Umar; Scholastika Iipinge; Friedel Dausab; Andrea Wirtz; Chris Beyrer Journal: AIDS Behav Date: 2011-08
Authors: Jonathan Z Li; Roger Paredes; Heather J Ribaudo; Evguenia S Svarovskaia; Karin J Metzner; Michael J Kozal; Kathy Huppler Hullsiek; Melanie Balduin; Martin R Jakobsen; Anna Maria Geretti; Rodolphe Thiebaut; Lars Ostergaard; Bernard Masquelier; Jeffrey A Johnson; Michael D Miller; Daniel R Kuritzkes Journal: JAMA Date: 2011-04-06 Impact factor: 56.272
Authors: Yinfeng Zhang; William Clarke; Mark A Marzinke; Estelle Piwowar-Manning; Geetha Beauchamp; Autumn Breaud; Craig W Hendrix; Gavin A Cloherty; Lynda Emel; Scott Rose; Lisa Hightow-Weidman; Marc Siegel; Steven Shoptaw; Sheldon D Fields; Darrell Wheeler; Susan H Eshleman Journal: Antimicrob Agents Chemother Date: 2017-06-27 Impact factor: 5.191
Authors: Michael J Silverberg; Wendy Leyden; Michael A Horberg; Gerald N DeLorenze; Daniel Klein; Charles P Quesenberry Journal: Arch Intern Med Date: 2007-04-09
Authors: Ravindra K Gupta; Michael R Jordan; Binta J Sultan; Andrew Hill; Daniel H J Davis; John Gregson; Anthony W Sawyer; Raph L Hamers; Nicaise Ndembi; Deenan Pillay; Silvia Bertagnolio Journal: Lancet Date: 2012-07-23 Impact factor: 79.321
Authors: Tonia Poteat; Benjamin Ackerman; Daouda Diouf; Nuha Ceesay; Tampose Mothopeng; Ky-Zerbo Odette; Seni Kouanda; Henri Gautier Ouedraogo; Anato Simplice; Abo Kouame; Zandile Mnisi; Gift Trapence; L Leigh Ann van der Merwe; Vicente Jumbe; Stefan Baral Journal: PLoS Med Date: 2017-11-07 Impact factor: 11.069
Authors: James Stannah; Elizabeth Dale; Jocelyn Elmes; Roisin Staunton; Chris Beyrer; Kate M Mitchell; Marie-Claude Boily Journal: Lancet HIV Date: 2019-10-07 Impact factor: 12.767
Authors: Mariya V Sivay; Philip J Palumbo; Yinfeng Zhang; Vanessa Cummings; Xu Guo; Erica L Hamilton; Laura McKinstry; Arthur Ogendo; Noel Kayange; Ravindre Panchia; Karen Dominguez; Ying Q Chen; Theodorus G M Sandfort; Susan H Eshleman Journal: Clin Infect Dis Date: 2021-07-01 Impact factor: 9.079
Authors: Sarah J Robbins; Wuese Dauda; Afoke Kokogho; Nicaise Ndembi; Andrew Mitchell; Sylvia Adebajo; Charlotte A Gaydos; Sheila Peel; Habib O Ramadhani; Merlin L Robb; Stefan D Baral; Julie A Ake; Man E Charurat; Trevor A Crowell; Rebecca G Nowak Journal: PLoS One Date: 2020-09-04 Impact factor: 3.240
Authors: Theo G M Sandfort; Karen Dominguez; Noel Kayange; Arthur Ogendo; Ravindre Panchia; Ying Q Chen; Wairimu Chege; Vanessa Cummings; Xu Guo; Erica L Hamilton; Michael Stirratt; Susan H Eshleman Journal: PLoS One Date: 2019-05-31 Impact factor: 3.240
Authors: Philip J Palumbo; Yinfeng Zhang; William Clarke; Autumn Breaud; Mariya Sivay; Vanessa Cummings; Erica L Hamilton; Xu Guo; Arthur Ogendo; Noel Kayange; Ravindre Panchia; Karen Dominguez; Ying Q Chen; Theodorus G M Sandfort; Susan H Eshleman Journal: Int J Infect Dis Date: 2021-01-10 Impact factor: 12.074
Authors: Dylan Green; Diana M Tordoff; Brenda Kharono; Adam Akullian; Anna Bershteyn; Michelle Morrison; Geoff Garnett; Ann Duerr; Paul K Drain Journal: J Int AIDS Soc Date: 2020-03 Impact factor: 5.396
Authors: Wendy Grant-McAuley; Jessica M Fogel; Noya Galai; William Clarke; Autumn Breaud; Mark A Marzinke; Jessie Mbwambo; Samuel Likindikoki; Said Aboud; Yeycy Donastorg; Martha Perez; Clare Barrington; Wendy Davis; Deanna Kerrigan; Susan H Eshleman Journal: PLoS One Date: 2020-10-29 Impact factor: 3.240